Trials / Terminated
TerminatedNCT01068470
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Loma Linda University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.
Detailed description
Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.
Conditions
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-12-01
- Completion
- 2012-03-01
- First posted
- 2010-02-15
- Last updated
- 2014-05-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01068470. Inclusion in this directory is not an endorsement.